RU2020129401A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020129401A3 RU2020129401A3 RU2020129401A RU2020129401A RU2020129401A3 RU 2020129401 A3 RU2020129401 A3 RU 2020129401A3 RU 2020129401 A RU2020129401 A RU 2020129401A RU 2020129401 A RU2020129401 A RU 2020129401A RU 2020129401 A3 RU2020129401 A3 RU 2020129401A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18158169 | 2018-02-22 | ||
| EP18158169.5 | 2018-02-22 | ||
| EP18189562 | 2018-08-17 | ||
| EP18189562.4 | 2018-08-17 | ||
| EP18194549.4 | 2018-09-14 | ||
| EP18194549.4A EP3623382A1 (en) | 2018-09-14 | 2018-09-14 | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| US16/269,572 US11655293B2 (en) | 2018-02-22 | 2019-02-07 | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| US16269572 | 2019-02-07 | ||
| PCT/EP2019/054493 WO2019162472A1 (en) | 2018-02-22 | 2019-02-22 | Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2020129401A RU2020129401A (ru) | 2022-03-22 |
| RU2020129401A3 true RU2020129401A3 (enExample) | 2022-03-22 |
| RU2772132C2 RU2772132C2 (ru) | 2022-05-18 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| JP7278296B2 (ja) | 2023-05-19 |
| BR112020017253A2 (pt) | 2020-12-22 |
| MX2020008792A (es) | 2020-10-14 |
| RU2020129401A (ru) | 2022-03-22 |
| JP2021514368A (ja) | 2021-06-10 |
| US20210070851A1 (en) | 2021-03-11 |
| US11655293B2 (en) | 2023-05-23 |
| US20190256587A1 (en) | 2019-08-22 |
| MA51893A (fr) | 2020-12-30 |
| KR20200123434A (ko) | 2020-10-29 |
| CN111886248B (zh) | 2025-03-04 |
| EP3755715A1 (en) | 2020-12-30 |
| CA3091536A1 (en) | 2019-08-29 |
| WO2019162472A1 (en) | 2019-08-29 |
| US20230340100A1 (en) | 2023-10-26 |
| MX2023001357A (es) | 2023-02-27 |
| US12384839B2 (en) | 2025-08-12 |
| AU2019224550A1 (en) | 2020-09-17 |
| CN111886248A (zh) | 2020-11-03 |